Live Webcast and Conference Call Scheduled for Thursday, March 27TH AT 5 PM
TUCSON, Ariz., March 20 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Thursday, March 27, 2008, at 5:00 p.m. ET to discuss corporate updates and fourth quarter 2007 financial results.
The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.
Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 3, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.
Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995
Note: Statements made in this press release which are not historical in
nature constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
Such statements include but are not limited those related to our efforts to
grow the marketplace for urokinase, our intent to reduce our operating
expenses associated with our SonoLysis development and our belief that we
will allow the Company to explore additional therapeutic applications for
the product. These statements are based on management's current
expectations and beliefs and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from
those described in the forward- looking statements. Such risks and
uncertainties include but are not limited to: sales of and demand for
urokinase may decline, the FDA may not approve our future requests for
urokinase lot releases or approval of expanded uses of urokinase beyond
treatment of acute massive pulmonary emboli, we may not be able to complete
definitive documentation with Microbix on the terms of our letter of
intent, Microbix may not be able to perfect the manufacturing process or to
secure approval from the FDA to manufacture urokinase, we may not be
effective in our marketing efforts for urokinase, and we may not have or be
able to secure sufficient capital to fund our operations and the
development and commercialization of our product candidates. All
information in this press release is as of January 30, 2008, and the
Company undertakes no duty to update this information. A more complete
description of these risks can be found in the Company's filings with the
Securities and Exchange Commission.
The Ruth Group
Sara Ephraim (investors)
Jason Rando (media)
|SOURCE ImaRx Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved